Endocrine therapy for breast cancer: an overview

被引：50

作者：

Cheung, K. L. ^{[1
]}

机构：

[1] Univ Nottingham, City Hosp, Div Breast Surg, Nottingham NG5 1PB, England

来源：

BREAST | 2007年 / 16卷 / 04期

关键词：

endocrine therapy; breast cancer;

D O I：

10.1016/j.breast.2007.03.004

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Endocrine therapy for breast cancer has been established in the adjuvant treatment for primary. disease and in the treatment of advanced disease. The ER remains the best predictor of response although other factors exist and need to be identified. Pharmacological manipulation has been replacing ablative procedures. Tamoxifen used to be the most popular agent of choice and promising new agents include the pure anti-oestrogens and the third generation selective aromatase inhibitors. Ongoing and future studies Will optimise treatment in established areas and will exploit its potential roles in preoperative use and chemoprevention. (C) 2007 Elsevier Ltd. All rights reserved.

引用

页码：327 / 343

页数：17

共 146 条

[21] Switching to anastrozole versus continued tamoxifen treatment of early breast cancer: Preliminary results of the Italian Tamoxifen Anastrozole trial [J].

Boccardo, F ;

Rubagotti, A ;

Puntoni, M ;

Guglielmini, P ;

Amoroso, D ;

Fini, A ;

Paladini, G ;

Mesiti, M ;

Romeo, D ;

Rinaldini, M ;

Scali, S ;

Porpiglia, M ;

Benedetto, C ;

Restuccia, N ;

Buzzi, F ;

Franchi, R ;

Massidda, B ;

Distante, V ;

Amadori, D ;

Sismondi, P .

JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (22) :5138-5147

[22] Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women:: Results of the tamoxifen or arimidex randomized group efficacy and tolerability study [J].

Bonneterre, J ;

Thürlimann, B ;

Robertson, JFR ;

Krzakowski, M ;

Mauriac, L ;

Koralewski, P ;

Vergote, I ;

Webster, A ;

Steinberg, M ;

von Euler, M .

JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (22) :3748-3757

[23]

Buzdar AU, 2005, CLIN CANCER RES, V11, p906S

[24]

Buzdar AU, 1997, CANCER, V79, P730, DOI 10.1002/(SICI)1097-0142(19970215)79:4<730::AID-CNCR10>3.0.CO

[25]

2-0

[26]

Buzdar AU, 1998, CANCER-AM CANCER SOC, V83, P1142, DOI 10.1002/(SICI)1097-0142(19980915)83:6<1142::AID-CNCR13>3.3.CO

[27]

2-7

[28]

CARLSON R, 2004, BREAST CANC RES T S1, V88

[29] Adjuvant chemotherapy followed by goserelin versus either modality alone for premenopausal lymph node-negative breast cancer: A randomized trial [J].

Castiglione-Gertsch, M ;

O'Neill, A ;

Price, KN ;

Goldhirsch, A ;

Coates, AS ;

Colleoni, M ;

Nasi, ML ;

Bonetti, M ;

Gelber, RD .

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2003, 95 (24) :1833-1846

[30]

CHEUNG K, 2007, WINT SCI M PATH SOC, P54

← 1 2 3 4 5 6 7 8 9 10 →